MX2024010899A - Formulación acuosa estable de un anticuerpo anti-adrenomedulina (adm) o fragmento de anticuerpo anti-adm. - Google Patents
Formulación acuosa estable de un anticuerpo anti-adrenomedulina (adm) o fragmento de anticuerpo anti-adm.Info
- Publication number
- MX2024010899A MX2024010899A MX2024010899A MX2024010899A MX2024010899A MX 2024010899 A MX2024010899 A MX 2024010899A MX 2024010899 A MX2024010899 A MX 2024010899A MX 2024010899 A MX2024010899 A MX 2024010899A MX 2024010899 A MX2024010899 A MX 2024010899A
- Authority
- MX
- Mexico
- Prior art keywords
- adm
- antibody
- adrenomedulin
- stable aqueous
- aqueous formulation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Cardiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22162271 | 2022-03-15 | ||
| PCT/EP2023/056663 WO2023175035A1 (en) | 2022-03-15 | 2023-03-15 | Stable aqueous formulation of an anti-adrenomedullin (adm) antibody or anti-adm antibody fragment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024010899A true MX2024010899A (es) | 2024-12-06 |
Family
ID=80780591
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024010899A MX2024010899A (es) | 2022-03-15 | 2024-09-05 | Formulación acuosa estable de un anticuerpo anti-adrenomedulina (adm) o fragmento de anticuerpo anti-adm. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250304671A1 (https=) |
| EP (1) | EP4493588A1 (https=) |
| JP (1) | JP2025509304A (https=) |
| CN (1) | CN119072492A (https=) |
| AU (1) | AU2023233838A1 (https=) |
| CA (1) | CA3254142A1 (https=) |
| IL (1) | IL315632A (https=) |
| MX (1) | MX2024010899A (https=) |
| WO (1) | WO2023175035A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025056807A1 (en) * | 2023-09-15 | 2025-03-20 | Basf Se | Stabilized biopolymer composition, their manufacture and use |
| WO2025133235A1 (en) * | 2023-12-22 | 2025-06-26 | Pam Theragnostics Gmbh | Adm-gly as marker for early predicting sepsis |
| WO2026046978A1 (en) * | 2024-08-26 | 2026-03-05 | Pam Theragnostics Gmbh | Anti-adm antibodies, anti-adm antibody fragment or anti-adm non-ig scaffold for therapy or prevention of immune effector cell therapy side effects |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| EP1690934A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| EP0585287B1 (en) | 1990-07-10 | 1999-10-13 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| CA2124967C (en) | 1991-12-17 | 2008-04-08 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| AU2002213441B2 (en) * | 2000-10-12 | 2006-10-26 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
| RU2004109222A (ru) | 2001-08-30 | 2005-10-20 | Байорексис Фармасьютикал Корпорейшн (Us) | Слитые белки модифицированного трансферрина |
| EP1620734A1 (en) | 2003-04-25 | 2006-02-01 | Genova Ltd. | Secreted polypeptide species reduced cardiovascular disorders |
| WO2005040229A2 (en) | 2003-10-24 | 2005-05-06 | Avidia, Inc. | Ldl receptor class a and egf domain monomers and multimers |
| US20100028995A1 (en) | 2004-02-23 | 2010-02-04 | Anaphore, Inc. | Tetranectin Trimerizing Polypeptides |
| US20070280886A1 (en) | 2004-09-09 | 2007-12-06 | Bayer Healthcare Ag | Diagnostics and Therapeutics for Diseases Associated with Adrenomedullin Receptor (Amdr) |
| US8278262B2 (en) | 2004-09-21 | 2012-10-02 | Biontech Ag | Use of microproteins as tryptase inhibitors |
| DK2231860T3 (da) | 2007-12-19 | 2011-12-05 | Affibody Ab | Polypeptid afledt protein A og i stand til at binde PDGF |
| EP3785735A1 (en) | 2008-11-03 | 2021-03-03 | Molecular Partners AG | Binding proteins inhibiting the vegf-a receptor interaction |
| MX2012002428A (es) | 2009-08-27 | 2012-09-12 | Covagen Ag | Compuestos de union il-17 y usos medicos de los mismos. |
| AU2010332932B2 (en) | 2009-12-14 | 2013-01-17 | Navigo Proteins Gmbh | Modified ubiquitin proteins having a specific binding activity for the extradomain B of fibronectin |
| RU2569745C2 (ru) | 2010-06-08 | 2015-11-27 | Пиерис АГ | Мутеины липокалина слезы, связывающие альфа il-4 r |
| SG11201402362VA (en) | 2011-11-16 | 2014-06-27 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition |
| EP2780370B1 (en) | 2011-11-16 | 2019-09-25 | AdrenoMed AG | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation |
| PL2594588T3 (pl) | 2011-11-16 | 2014-11-28 | Adrenomed Ag | Przeciwciało przeciwko adrenomedulinie (ADM) lub fragment przeciwciała anty-ADM lub szkielet białkowy niestanowiący Ig anty-ADM do zastosowania w terapii |
| DK2780371T3 (en) | 2011-11-16 | 2019-02-25 | Adrenomed Ag | ANTI-ADDRENOMEDULLIN (ADM) ANTIBODY OR ANTI-ADM ANTISTOFFRAGMENT OR ANTI-ADM NON-IG TEMPLATE FOR REGULATING LIQUID BALANCE OF A PATIENT WITH A CHRONIC OR ACUTE DISEASE |
| EP4086283A1 (en) | 2011-11-16 | 2022-11-09 | AdrenoMed AG | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for prevention or reduction of organ dysfunction or organ failure in a patient having a chronic or acute disease or acute condition |
| AU2017252212B2 (en) | 2016-04-21 | 2023-09-07 | 4TEEN4 Pharmaceuticals GmbH | Methods for determining DPP3 and therapeutic methods |
| KR20240033285A (ko) | 2016-12-16 | 2024-03-12 | 아드레노메드 아게 | 울혈의 중재 및 치료가 필요한 환자에서 울혈의 중재 및 치료에 사용하기 위한 항-아드레노메둘린 (ADM) 항체 또는 항-ADM 항체 단편 또는 항-ADM 비-Ig 스캐폴드 |
| SG11202002268XA (en) * | 2017-10-18 | 2020-04-29 | Adrenomed Ag | Therapy monitoring under treatment with an anti-adrenomedullin (adm) binder |
| CA3168978A1 (en) * | 2020-02-27 | 2021-09-02 | Andreas Bergmann | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock |
-
2023
- 2023-03-15 CA CA3254142A patent/CA3254142A1/en active Pending
- 2023-03-15 CN CN202380036069.7A patent/CN119072492A/zh active Pending
- 2023-03-15 EP EP23711082.0A patent/EP4493588A1/en active Pending
- 2023-03-15 US US18/844,746 patent/US20250304671A1/en active Pending
- 2023-03-15 IL IL315632A patent/IL315632A/en unknown
- 2023-03-15 WO PCT/EP2023/056663 patent/WO2023175035A1/en not_active Ceased
- 2023-03-15 AU AU2023233838A patent/AU2023233838A1/en active Pending
- 2023-03-15 JP JP2024553456A patent/JP2025509304A/ja active Pending
-
2024
- 2024-09-05 MX MX2024010899A patent/MX2024010899A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2023233838A1 (en) | 2024-09-26 |
| WO2023175035A1 (en) | 2023-09-21 |
| CA3254142A1 (en) | 2023-09-21 |
| CN119072492A (zh) | 2024-12-03 |
| EP4493588A1 (en) | 2025-01-22 |
| IL315632A (en) | 2024-11-01 |
| US20250304671A1 (en) | 2025-10-02 |
| JP2025509304A (ja) | 2025-04-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024010899A (es) | Formulación acuosa estable de un anticuerpo anti-adrenomedulina (adm) o fragmento de anticuerpo anti-adm. | |
| WO2019171253A8 (en) | Anti-pd-1 antibody compositions | |
| MX2025010757A (es) | Formulacion farmaceutica de ph bajo | |
| AR130402A2 (es) | Formulaciones de anticuerpos anti-pdl1 | |
| CU20190015A7 (es) | Formulaciones de anticuerpos inhibidores de masp-2 altamente concentrados, de baja viscosidad y composiciones farmacéuticas que las comprenden | |
| CL2019002250A1 (es) | Anticuerpos anti-b7-h3 y conjugados de anticuerpo y fármaco. (divisional solicitud 201803520) | |
| EP4650371A3 (en) | Antibody-containing preparation | |
| CY1122181T1 (el) | Φαρμακοτεχνικη μορφη αντισωματος | |
| CO2017007693A2 (es) | Formulación acuosa estable de anticuerpo anti-factor de crecimiento celular endotelial vascular (vegf) | |
| MX2019010408A (es) | Formulacion de anticuerpo monoclonal anti-vrs. | |
| CO2021010697A2 (es) | Formulación de anticuerpos terapéuticos | |
| AR092401A1 (es) | Formulaciones de anticuerpos anti-receptor de prolactina (anti-prlr) | |
| CO6251275A2 (es) | Formulaciones de inmunoglobulina liofilizadas y metodos para su preparacion | |
| CO2020013571A2 (es) | Formulaciones estables de anticuerpos terapéuticos | |
| NO20080612L (no) | Immunokonjugatpreparater | |
| IL274897B2 (en) | Formulations of dengue virus vaccine compositions | |
| SA521421715B1 (ar) | تركيبات سيماجلوتيد ثابتة واستخداماتها | |
| MX2021015298A (es) | Anticuerpo anti-epha4 humano. | |
| BR112021019959A2 (pt) | Anticorpo biespecífico, e, formulação farmacêutica | |
| MX2021007393A (es) | Formulacion de solucion de proteinas que contiene una alta concentracion de un anticuerpo anti-vegf. | |
| AR097840A1 (es) | Una formulación de un conjugado de la hormona de crecimiento humana de la actividad prolongada, procedimiento, kit | |
| AR115365A1 (es) | Formulaciones de anticuerpos anti-pd-l1 humanos | |
| MX2023001160A (es) | Composicion farmaceutica del anticuerpo anti-pd-1 y uso del mismo. | |
| EA202192568A1 (ru) | Стабилизированные составы, содержащие антитела к il-33 | |
| CO2022005737A2 (es) | Formulación estable de anticuerpo de integrina |